ALK-positive cancer: still a growing entity.

 Since the discovery of ALK-positive anaplastic large-cell lymphoma in 1994 many other types of tumors showing ALK expression were disclosed. They form a heterogeneous group, including lung, renal and soft tissue tumors. The biological function of ALK, its role in carcinogenesis and impact exerted on the clinical outcome have been studied by many research groups. New drugs specifically dedicated for ALK inhibition, for example, crizotinib, have been synthesized and have become a viable treatment option for ALK-positive lung adenocarcinoma, and potentially for other ALK-positive cancers. This review summarizes the current state of knowledge concerning ALK-positive neoplasms, focusing on the clinical aspects of the subject.

[1]  M. Bzorek,et al.  Expression of anaplastic lymphoma kinase in Merkel cell carcinomas. , 2013, Human pathology.

[2]  T. Whitton,et al.  Molecular and functional characterizations of the association and interactions between nucleophosmin-anaplastic lymphoma kinase and type I insulin-like growth factor receptor. , 2013, Neoplasia.

[3]  L. Diao,et al.  NPM‐ALK up‐regulates iNOS expression through a STAT3/microRNA‐26a‐dependent mechanism , 2013, The Journal of pathology.

[4]  J. Maris,et al.  Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. , 2013, The Lancet. Oncology.

[5]  K. Broadie,et al.  Jelly belly trans‐synaptic signaling to anaplastic lymphoma kinase regulates neurotransmission strength and synapse architecture , 2013, Developmental neurobiology.

[6]  K. Savage,et al.  Anaplastic large cell lymphoma, ALK-negative. , 2013, Critical reviews in oncology/hematology.

[7]  J. Christensen,et al.  Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells , 2012, Oncogene.

[8]  J. Cheville,et al.  ALK alterations in adult renal cell carcinoma: frequency, clinicopathologic features and outcome in a large series of consecutively treated patients , 2012, Modern Pathology.

[9]  M. Marra,et al.  Cell culture and Drosophila model systems define three classes of anaplastic lymphoma kinase mutations in neuroblastoma , 2012, Disease Models & Mechanisms.

[10]  Y. Ishikawa,et al.  Identification of anaplastic lymphoma kinase fusions in renal cancer , 2012, Cancer.

[11]  N. Bartlett,et al.  Brentuximab Vedotin and Crizotinib in Anaplastic Large-Cell Lymphoma , 2012, Cancer journal.

[12]  L. Gong,et al.  Extra copies of ALK gene locus is a recurrent genetic aberration and favorable prognostic factor in both ALK-positive and ALK-negative anaplastic large cell lymphomas. , 2012, Leukemia research.

[13]  Roman K. Thomas,et al.  Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants , 2012, Clinical Cancer Research.

[14]  A. Oberthuer,et al.  Identification of ALK germline mutation (3605delG) in pediatric anaplastic medulloblastoma , 2012, Journal of Human Genetics.

[15]  R. Lai,et al.  NPM-ALK: The Prototypic Member of a Family of Oncogenic Fusion Tyrosine Kinases , 2012, Journal of signal transduction.

[16]  Bandana Sharma,et al.  The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma. , 2012, Cancer cell.

[17]  A. Warth,et al.  A Novel EML4-ALK Variant: Exon 6 of EML4 Fused to Exon 19 of ALK , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[18]  Zi-fen Gao,et al.  [ALK positive large B-cell lymphoma: a case report]. , 2012, Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi.

[19]  P. Kim,et al.  Discovery of ALK‐PTPN3 gene fusion from human non‐small cell lung carcinoma cell line using next generation RNA sequencing , 2012, Genes, chromosomes & cancer.

[20]  D. Bell,et al.  ALK-1 protein expression and ALK gene rearrangements aid in the diagnosis of inflammatory myofibroblastic tumors of the female genital tract. , 2012, Archives of pathology & laboratory medicine.

[21]  Rani E. George,et al.  Promising Therapeutic Targets in Neuroblastoma , 2012, Clinical Cancer Research.

[22]  I. Wistuba,et al.  MicroRNA 96 is a post-transcriptional suppressor of anaplastic lymphoma kinase expression. , 2012, The American journal of pathology.

[23]  E. Morgan,et al.  Anaplastic Lymphoma Kinase-Positive Large B-Cell Lymphoma: An Underrecognized Aggressive Lymphoma , 2012, Advances in hematology.

[24]  T. Nakajima,et al.  KLC1-ALK: A Novel Fusion in Lung Cancer Identified Using a Formalin-Fixed Paraffin-Embedded Tissue Only , 2012, PloS one.

[25]  R. Tuma.  ALK gene amplified in most inflammatory breast cancers. , 2012, Journal of the National Cancer Institute.

[26]  Huaqing Zhao,et al.  Differential Inhibitor Sensitivity of Anaplastic Lymphoma Kinase Variants Found in Neuroblastoma , 2011, Science Translational Medicine.

[27]  R. Palmer,et al.  ALK and NSCLC: Targeted therapy with ALK inhibitors , 2011, F1000 medicine reports.

[28]  Jeffrey W. Clark,et al.  Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. , 2011, The Lancet. Oncology.

[29]  T. Kohno,et al.  Comprehensive Histologic Analysis of ALK-Rearranged Lung Carcinomas , 2011, The American journal of surgical pathology.

[30]  Y. Jou,et al.  Identification of oncogenic point mutations and hyperphosphorylation of anaplastic lymphoma kinase in lung cancer. , 2011, Neoplasia.

[31]  Ryohei Katayama,et al.  Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK , 2011, Proceedings of the National Academy of Sciences.

[32]  W. Klapper,et al.  Inhibition of Anaplastic Lymphoma Kinase (ALK) Activity Provides a Therapeutic Approach for CLTC-ALK-Positive Human Diffuse Large B Cell Lymphomas , 2011, PloS one.

[33]  Y. Ishikawa,et al.  Pulmonary Inflammatory Myofibroblastic Tumor Expressing a Novel Fusion, PPFIBP1–ALK: Reappraisal of Anti-ALK Immunohistochemistry as a Tool for Novel ALK Fusion Identification , 2011, Clinical Cancer Research.

[34]  M. Soda,et al.  Identification of a novel fusion, SQSTM1-ALK, in ALK-positive large B-cell lymphoma , 2011, Haematologica.

[35]  J. Fletcher,et al.  ALK rearrangement in sickle cell trait‐associated renal medullary carcinoma , 2011, Genes, chromosomes & cancer.

[36]  S. Raimondi,et al.  Renal cell carcinoma with novel VCL–ALK fusion: new representative of ALK-associated tumor spectrum , 2011, Modern Pathology.

[37]  C. Messa,et al.  Crizotinib in anaplastic large-cell lymphoma. , 2011, The New England journal of medicine.

[38]  Michael Hummel,et al.  Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL. , 2010, Blood.

[39]  Jeffrey W. Clark,et al.  Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. , 2010, The New England journal of medicine.

[40]  Takashi Yamasaki,et al.  Combination of morphological feature analysis and immunohistochemistry is useful for screening of EML4-ALK-positive lung adenocarcinoma , 2010, Journal of Clinical Pathology.

[41]  Frank Speleman,et al.  Meta-analysis of Neuroblastomas Reveals a Skewed ALK Mutation Spectrum in Tumors with MYCN Amplification , 2010, Clinical Cancer Research.

[42]  E. Lasorsa,et al.  Involvement of Grb2 Adaptor Protein in Nucleophosmin-Anaplastic Lymphoma Kinase (NPM-ALK)-mediated Signaling and Anaplastic Large Cell Lymphoma Growth* , 2010, The Journal of Biological Chemistry.

[43]  Stephen L. Abrams,et al.  The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy. , 2010, Cell cycle.

[44]  A. Yoshizawa,et al.  Clinicopathologic Features of Non-Small-Cell Lung Cancer with EML4–ALK Fusion Gene , 2010, Annals of Surgical Oncology.

[45]  H. Mano,et al.  EML4-ALK fusion in lung. , 2010, The American journal of pathology.

[46]  J. Delabie,et al.  ALK-positive large B-cell lymphomas with cryptic SEC31A-ALK and NPM1-ALK fusions , 2010, Haematologica.

[47]  A. Wellstein,et al.  Effect of single-chain antibody targeting of the ligand-binding domain in the anaplastic lymphoma kinase receptor , 2009, Oncogene.

[48]  S. Digumarthy,et al.  Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  Li Li,et al.  Exon Array Profiling Detects EML4-ALK Fusion in Breast, Colorectal, and Non–Small Cell Lung Cancers , 2009, Molecular Cancer Research.

[50]  A. Iafrate,et al.  Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western Population , 2009, Clinical Cancer Research.

[51]  L. Kwak,et al.  IGF-IR tyrosine kinase interacts with NPM-ALK oncogene to induce survival of T-cell ALK+ anaplastic large-cell lymphoma cells. , 2009, Blood.

[52]  Y. Ishikawa,et al.  KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer , 2009, Clinical Cancer Research.

[53]  L. Medeiros,et al.  Sonic hedgehog signaling pathway is activated in ALK-positive anaplastic large cell lymphoma. , 2009, Cancer research.

[54]  E. Campo,et al.  EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. , 2009, The American journal of pathology.

[55]  Florian Steinberg,et al.  Enhanced antitumorigenic effects in glioblastoma on double targeting of pleiotrophin and its receptor ALK. , 2009, Neoplasia.

[56]  H. Carén,et al.  High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours. , 2008, The Biochemical journal.

[57]  John M. Maris,et al.  Identification of ALK as a major familial neuroblastoma predisposition gene , 2008, Nature.

[58]  Gudrun Schleiermacher,et al.  Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma , 2008, Nature.

[59]  D. Weisenburger,et al.  International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  B. Groner,et al.  The function of Stat3 in tumor cells and their microenvironment. , 2008, Seminars in cell & developmental biology.

[61]  Kihyun Kim,et al.  ALK‐positive diffuse large B‐cell lymphoma: report of three cases , 2008, Hematological oncology.

[62]  J. LoPiccolo,et al.  Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. , 2008, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[63]  J. Turkson,et al.  STAT3 as a target for inducing apoptosis in solid and hematological tumors , 2008, Cell Research.

[64]  Petr Znamenskiy,et al.  Behavioral and Neurochemical Alterations in Mice Deficient in Anaplastic Lymphoma Kinase Suggest Therapeutic Potential for Psychiatric Indications , 2008, Neuropsychopharmacology.

[65]  N. Shinton.  WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues , 2007 .

[66]  M. Wasik,et al.  STAT5A is epigenetically silenced by the tyrosine kinase NPM1-ALK and acts as a tumor suppressor by reciprocally inhibiting NPM1-ALK expression , 2007, Nature Medicine.

[67]  H. Aburatani,et al.  Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.

[68]  P. Pérez-Piñera,et al.  Anaplastic lymphoma kinase is expressed in different subtypes of human breast cancer. , 2007, Biochemical and biophysical research communications.

[69]  C. Fletcher,et al.  Inflammatory Myofibroblastic Tumor: Comparison of Clinicopathologic, Histologic, and Immunohistochemical Features Including ALK Expression in Atypical and Aggressive Cases , 2007, The American journal of surgical pathology.

[70]  S. Kroft,et al.  ALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literature , 2007, Modern Pathology.

[71]  P. Gaulard,et al.  Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes. , 2007, Blood.

[72]  Q. Zhan,et al.  Proteomic profiling of proteins dysregulted in Chinese esophageal squamous cell carcinoma , 2007, Journal of Molecular Medicine.

[73]  P Wlodarski,et al.  Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf , 2007, Oncogene.

[74]  Peter G. Schultz,et al.  Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK , 2007, Proceedings of the National Academy of Sciences.

[75]  R. Malekzadeh,et al.  Identification of squamous cell carcinoma associated proteins by proteomics and loss of beta tropomyosin expression in esophageal cancer. , 2006, World journal of gastroenterology.

[76]  R. Lai,et al.  Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK+ anaplastic large-cell lymphoma. , 2006, Blood.

[77]  D. Calame,et al.  Autocrine release of interleukin-9 promotes Jak3-dependent survival of ALK+ anaplastic large-cell lymphoma cells. , 2006, Blood.

[78]  F. Mertens,et al.  Fusion of the SEC31L1 and ALK genes in an inflammatory myofibroblastic tumor , 2006, International journal of cancer.

[79]  G. Bepler,et al.  Activated Epidermal Growth Factor Receptor–Stat-3 Signaling Promotes Tumor Survival In vivo in Non–Small Cell Lung Cancer , 2005, Clinical Cancer Research.

[80]  D. Rodeberg,et al.  Pediatric inflammatory myofibroblastic tumor: Anaplastic lymphoma kinase (ALK) expression and prognosis , 2005, Pediatric blood & cancer.

[81]  G. Rassidakis,et al.  Jak3 activation is significantly associated with ALK expression in anaplastic large cell lymphoma. , 2005, Human pathology.

[82]  D. Alexander,et al.  What have we learnt from mouse models of NPM-ALK-induced lymphomagenesis? , 2005, Leukemia.

[83]  G. Rassidakis,et al.  Inhibition of Akt increases p27Kip1 levels and induces cell cycle arrest in anaplastic large cell lymphoma. , 2005, Blood.

[84]  T. McDonnell,et al.  Selective inhibition of STAT3 induces apoptosis and G1 cell cycle arrest in ALK-positive anaplastic large cell lymphoma , 2004, Oncogene.

[85]  Xiong-zeng Zhu,et al.  Expression of anaplastic lymphoma kinase in soft tissue tumors: an immunohistochemical and molecular study of 249 cases. , 2004, Human pathology.

[86]  Angelo Rosolen,et al.  Ubiquitination and proteasomal degradation of nucleophosmin-anaplastic lymphoma kinase induced by 17-allylamino-demethoxygeldanamycin: role of the co-chaperone carboxyl heat shock protein 70-interacting protein. , 2004, Cancer research.

[87]  G. Delsol,et al.  Nucleophosmin-anaplastic lymphoma kinase of anaplastic large-cell lymphoma recruits, activates, and uses pp60c-src to mediate its mitogenicity. , 2003, Blood.

[88]  M. Lovell,et al.  Recurrent inflammatory pseudotumors in children. , 2003, Journal of pediatric surgery.

[89]  J. Downing,et al.  ALK-positive plasmablastic B-cell lymphoma with expression of the NPM-ALK fusion transcript: report of 2 cases. , 2003, Blood.

[90]  P. Marynen,et al.  ALK‐ATIC fusion in urinary bladder inflammatory myofibroblastic tumor , 2003, Genes, chromosomes & cancer.

[91]  P. Marynen,et al.  ALK activation by the CLTC-ALK fusion is a recurrent event in large B-cell lymphoma. , 2003, Blood.

[92]  T. McDonnell,et al.  Inhibition of JAK3 induces apoptosis and decreases anaplastic lymphoma kinase activity in anaplastic large cell lymphoma , 2003, Oncogene.

[93]  R. Gascoyne,et al.  Non‐muscle myosin heavy chain (MYH9): A new partner fused to ALK in anaplastic large cell lymphoma , 2003, Genes, chromosomes & cancer.

[94]  Ming Zhou,et al.  Fusion of ALK to the Ran‐binding protein 2 (RANBP2) gene in inflammatory myofibroblastic tumor , 2003, Genes, chromosomes & cancer.

[95]  C. Powers,et al.  Midkine Binds to Anaplastic Lymphoma Kinase (ALK) and Acts as a Growth Factor for Different Cell Types* , 2002, The Journal of Biological Chemistry.

[96]  P. Marynen,et al.  Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large‐cell lymphoma and inflammatory myofibroblastic tumor , 2002, Genes, chromosomes & cancer.

[97]  H. Drexler,et al.  Expression and functional analysis of the anaplastic lymphoma kinase (ALK) gene in tumor cell lines , 2002, International journal of cancer.

[98]  C. Meijer,et al.  Expression levels of apoptosis-related proteins predict clinical outcome in anaplastic large cell lymphoma. , 2002, Blood.

[99]  C. Powers,et al.  Pleiotrophin Signaling through Anaplastic Lymphoma Kinase Is Rate-limiting for Glioblastoma Growth* , 2002, The Journal of Biological Chemistry.

[100]  Beatriz Bellosillo,et al.  Diversity of genomic breakpoints in TFG-ALK translocations in anaplastic large cell lymphomas: identification of a new TFG-ALK(XL) chimeric gene with transforming activity. , 2002, The American journal of pathology.

[101]  S. Morris,et al.  Anaplastic Lymphoma Kinase (ALK) Expression in the Inflammatory Myofibroblastic Tumor: A Comparative Immunohistochemical Study , 2001, The American journal of surgical pathology.

[102]  L. Meltesen,et al.  Unusual childhood extramedullary hematologic malignancy with natural killer cell properties that contains tropomyosin 4--anaplastic lymphoma kinase gene fusion. , 2001, Blood.

[103]  M. Ladanyi,et al.  Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor. , 2001, The American journal of pathology.

[104]  S. Perkins,et al.  ALK1 and p80 Expression and Chromosomal Rearrangements Involving 2p23 in Inflammatory Myofibroblastic Tumor , 2001, Modern Pathology.

[105]  D. Wen,et al.  Identification of Anaplastic Lymphoma Kinase as a Receptor for the Growth Factor Pleiotrophin* , 2001, The Journal of Biological Chemistry.

[106]  E. Campo,et al.  Molecular Characterization of a New ALK Translocation Involving Moesin (MSN-ALK) in Anaplastic Large Cell Lymphoma , 2001, Laboratory Investigation.

[107]  S. Morris,et al.  Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway. , 2000, Blood.

[108]  P. D. Dal Cin,et al.  TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors. , 2000, The American journal of pathology.

[109]  K. Pulford,et al.  Further demonstration of the diversity of chromosomal changes involving 2p23 in ALK-positive lymphoma: 2 cases expressing ALK kinase fused to CLTCL (clathrin chain polypeptide-like). , 2000, Blood.

[110]  K. Pulford,et al.  Expression of the ALK tyrosine kinase gene in neuroblastoma. , 2000, The American journal of pathology.

[111]  M. Ladanyi,et al.  ATIC-ALK: A novel variant ALK gene fusion in anaplastic large cell lymphoma resulting from the recurrent cryptic chromosomal inversion, inv(2)(p23q35). , 2000, The American journal of pathology.

[112]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[113]  C. Griffin,et al.  Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors. , 1999, Cancer research.

[114]  T. Greiner,et al.  Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. , 1999, Blood.

[115]  K. Pulford,et al.  A new fusion gene TPM3-ALK in anaplastic large cell lymphoma created by a (1;2)(q25;p23) translocation. , 1999, Blood.

[116]  S. Pileri,et al.  ALK+ lymphoma: clinico-pathological findings and outcome. , 1999, Blood.

[117]  S. Morris,et al.  Nucleophosmin-Anaplastic Lymphoma Kinase of Large-Cell Anaplastic Lymphoma Is a Constitutively Active Tyrosine Kinase That Utilizes Phospholipase C-γ To Mediate Its Mitogenicity , 1998, Molecular and Cellular Biology.

[118]  John Calvin Reed,et al.  Regulation of cell death protease caspase-9 by phosphorylation. , 1998, Science.

[119]  C. Naeve,et al.  ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK) , 1997, Oncogene.

[120]  K. Pulford,et al.  Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. , 1997, Blood.

[121]  T. Arakawa,et al.  Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system , 1997, Oncogene.

[122]  D. Noh,et al.  Phosphoinositide-specific phospholipase C and mitogenic signaling. , 1995, Biochimica et biophysica acta.

[123]  M. Sasaki,et al.  A novel translocation, t(2;5)(p23;q35), in childhood phagocytic large T-cell lymphoma mimicking malignant histiocytosis. , 1989, Blood.

[124]  K. Lennert,et al.  The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. , 1985, Blood.

[125]  L. Tanoue,et al.  Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer , 2012 .

[126]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[127]  E. Medina,et al.  Anaplastic large cell lymphoma: twenty-five years of discovery. , 2011, Archives of pathology & laboratory medicine.

[128]  Stephen L. Abrams,et al.  Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy , 2011, Leukemia.

[129]  A. K. Murugan,et al.  Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene. , 2011, Cancer research.

[130]  H. Carén,et al.  Appearance of the novel activating F1174S ALK mutation in neuroblastoma correlates with aggressive tumor progression and unresponsiveness to therapy. , 2011, Cancer research.

[131]  M. Djokic.  ALK− anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project , 2009 .

[132]  H. Amin,et al.  Loss of SHP 1 enhances JAK 3 / STAT 3 signaling and decreases proteosome degradation of JAK 3 and NPM-ALK in ALK anaplastic large-cell lymphoma , 2006 .

[133]  筬島 裕子,et al.  Biological role of anaplastic lymphoma kinase in neuroblastoma , 2006 .

[134]  D N Shapiro,et al.  Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. , 1994, Science.

[135]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.